Immunogenicity and Safety Study of FSME-IMMUN 0.5 mL in Adult Subjects Previously Vaccinated According to a Rapid Immunization Schedule

Recruitment & Eligibility

Inclusion Criteria

Male and female subjects will be eligible for participation in this study if they:

Understand the nature of the study, agree to its provisions and provide written informed consent (assent if the subjects is under 18 years of age);
Provide the written informed consent of their parents / legal guardian (if the subject is under 18 years of age);
Are aged >= 16 years (from the 16th birthday) at screening;
Are clinically healthy, (i.e. the physician would have no reservations vaccinating with FSME-IMMUN 0.5 ml outside the scope of a clinical trial);
Have a negative pregnancy test result at the first medical examination (if female and capable of bearing children);
Agree to employ adequate birth control measures for the duration of the study (if female and capable of bearing children);
Agree to keep a Subject Diary.

Exclusion Criteria

Subjects will be excluded from participation in this study if they:

Have a history of any previous tick-borne encephalitis (TBE) vaccination;
Have a history of TBE infection;
Have a history of infection with or vaccination against other flaviviruses (e.g. dengue fever, yellow fever, Japanese B-encephalitis);
Have a history of allergic reactions, in particular to one of the components of the vaccine;
Suffer from a disease (e.g. autoimmune disease) or are undergoing a form of treatment (e.g. systemic corticosteroids) that can be expected to influence immunological functions;
Have a known or suspected problem with drug or alcohol abuse (> 4 liters wine / week or equivalent level of other alcoholic beverages);
Have donated blood or plasma within 30 days of study entry;
Have received a blood transfusion or immunoglobulins within 30 days of study entry;
Are known to be HIV positive (an HIV test is not required specifically for the purpose of this study);
Are simultaneously participating in another clinical trial including administration of an investigational product;
Have participated in any other clinical study within six weeks prior to study entry;
Are pregnant or breastfeeding (if female);
Are a member of the team conducting this study or are in a dependent relationship with the study investigator. Dependent relationships include close relatives (i.e., children, partner/spouse, siblings, parents) as well as employees of the investigator.
Have received any other vaccination within two weeks prior to study entry.

Study & Design

Primary Outcome Measures

Name	Time	Method
Immunogenicity: Seropositivity rate as determined by Enzyme-Linked Immunosorbent Assay (ELISA) and Neutralization test (NT) at Days 7, 14 and 21 after the second vaccination, in stratum A and B separately, and in the two age strata combined.

Secondary Outcome Measures

Name	Time	Method

Recruitment & Eligibility